Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Baxter
McKinsey
Julphar
Deloitte
Healthtrust

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 6,824,768

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,824,768
Title: Ribavirin-pegylated interferon alfa induction HCV combination therapy
Abstract:There is disclosed a method for treating antiviral treatment naives patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using (1) a therapeutically effective inducing amount of ribavirin and a therapeutically effective induction dosing amount of pegylated interferon-alfa, e.g, pegylated interferon-alfa-2b for a first treatment time period sufficient to substantially lower detectable HCV-RNA, followed by (2) administering a therapeutically effective amount of ribavirin and an therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b for a second treatment time period sufficient to eradicate detectable HCV-RNA at least by end of the second treatment time period and to maintain no detectable HCV-RNA for at least 24 weeks after the end of the second treatment time period.
Inventor(s): Stalgis; Carlos O. (Millington, NJ), Albrecht; Janice K. (Winter Park, FL), Glue; Paul W. (Flemington, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:09/464,426
Patent Claims:see list of patent claims

Details for Patent 6,824,768

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Sign Up Schering Corporation (Kenilworth, NJ) 2018-12-18 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Sign Up Schering Corporation (Kenilworth, NJ) 2018-12-18 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Sign Up Schering Corporation (Kenilworth, NJ) 2018-12-18 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cipla
AstraZeneca
Farmers Insurance
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.